MENLO PARK, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, announced today that Dr. Hannah Valantine has been nominated for election to the Company’s Board of Directors as a Class II director at the Company’s 2021 Annual Meeting of Stockholders. Dr. Valantine is currently a Professor of Medicine (Cardiovascular) at the Stanford University Medical Center and for the past seven years she has served as the Chief Officer for Scientific Workforce Diversity overseeing NIH efforts to increase diversity in biomedical research. In 2020, she was elected to the National Academy of Medicine for both her pioneering research in organ transplantation and workforce diversity.

Visit link:
Pacific Biosciences Nominates Dr. Hannah Valantine to its Board of Directors

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh